Premium
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
NEW YORK, June 22, 2020 (GLOBE NEWSWIRE) -- Proactive, the digital financial news organization, will be showcasing four rising stars of the life sciences industry with its first North American...
OTTAWA, May 15, 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSXV:TBP) (OTCQB:TBPMF), is pleased to announce that, in connection with its previously announced...
NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES OTTAWA, May 14, 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSXV:TBP) (OTCQB:TBPMF...
OTTAWA, April 06, 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased...
Bioanalytical methods developed and validated for its clinical trials. Tetra initiates study to quantify phytocannabinoid metabolites and precursors and minor phytocannabinoids in human plasma...
OTTAWA, March 30, 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. ("Tetra" or the "Corporation") (TSX-V: TBP) (OTCQB: TBPMF), announced today it has filed an amended and restated management’s...
OTTAWA, March 26, 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, today...
OTTAWA, March 23, 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, today would...
OTTAWA, March 06, 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V: TBP) (OTCQB: TBPMF), a leader in cannabinoid-derived drug discovery and development, is...
ORLEANS, Ontario, Aug. 12, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc., a leader in drug discovery and development for cannabinoid-based therapeutics, announced today the company has engaged...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0.215 | 0.215 | 0.215 | 0 | 0 | CS |
| 4 | 0 | 0 | 0.215 | 0.215 | 0.215 | 0 | 0 | CS |
| 12 | 0 | 0 | 0.215 | 0.215 | 0.215 | 0 | 0 | CS |
| 26 | 0 | 0 | 0.215 | 0.215 | 0.215 | 0 | 0 | CS |
| 52 | 0 | 0 | 0.215 | 0.215 | 0.215 | 0 | 0 | CS |
| 156 | 0 | 0 | 0.215 | 0.215 | 0.215 | 0 | 0 | CS |
| 260 | -0.23 | -51.6853932584 | 0.445 | 0.69 | 0.185 | 132021 | 0.33844171 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
